Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

AVTX stock hub

Avalo Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AVTXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

576.2M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AVTX

In the news

Latest news · AVTX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-72.4

P25 -105.6P50 -46.5P75 -3.1

ROIC-41.9

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AVTX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

202

Groups with data

Currency

USD

Showing 202 of 202 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001534120
Company name	Avalo Therapeutics, Inc.
Country	United States
Country code	US
Cusip	05338F108
Employees	33
Employees Change	10%
Employees Change Percent	43.48
Enterprise value	$478.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2015-10-15
Isin	US05338F3064
Last refreshed	2026-05-10
Market cap	$576.2M
Market cap category	Small-Cap
Price	$21.57
Price currency	USD
Rev Per Employee	1,787.88x
Sector	Healthcare
Sic	2834
Symbol	AVTX
Website	https://www.avalotx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-13.58%
EV/Sales	8,107.11x
FCF yield	-8.93%
P/B ratio	4.81x
P/S ratio	9,766.58x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-35.3M
Net Income	$-78.3M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-132,362.71%
Profit Per Employee	$-2.4M
ROA	-34.12
Roa5y	-46.71
ROCE	-70.45
ROE	-72.43
ROIC	-41.93

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-46.37%
Cagr1y	385.24%
Cagr3y	-67.42%
Cagr5y	-69.25%
EPS Growth Years	5
Revenue Growth	-86.62x
Revenue Growth Q	-69.27x
Revenue Growth Years	0x
Revenue Growth3 Y	-85.16x
Revenue Growth5 Y	-61.19x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0
Assets	$116.5M
Cash	$98.3M
Current Assets	$105.3M
Current Liabilities	$12.9M
Debt	$427,000
Debt Equity	$0.01
Equity	$83M
Liabilities	$33.4M
Long Term Assets	$11.2M
Long Term Liabilities	$20.5M
Net Cash	$97.9M
Net Cash By Market Cap	$16.99
Net Cash Growth	-26.73%
Net Debt Equity	$-1.18
Tangible Book Value	$72.5M
Tangible Book Value Per Share	$3.92
WACC	8.61

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.14
Net Working Capital	$-5.6M
Quick ratio	7.6
Working Capital	$92.3M
Working Capital Turnover	$0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-78.82%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-99.8%
1Y total return	384.72%
200-day SMA	14.57
3Y total return	-96.54%
50-day SMA	15.54
50-day SMA vs 200-day SMA	50over200
5Y total return	-99.72%
All Time High	22,031.5
All Time High Change	-99.9%
All Time High Date	2019-02-27
All Time Low	3.39
All Time Low Change	536.28%
All Time Low Date	2025-05-14
ATR	1.81
Beta	0.79
Beta1y	0.82
Beta2y	0.79
Ch YTD	18.78
High	22.97
High52	24.27
High52 Date	2026-05-07
High52ch	-11.12%
Low	20.98
Low52	3.39
Low52 Date	2025-05-14
Low52ch	536.28%
Ma50ch	38.79%
Premarket Change Percent	-2.4
Premarket Price	$22.32
Premarket Volume	2,636
Price vs 200-day SMA	48.07%
RSI	71.07
RSI Monthly	34.24
RSI Weekly	67.92
Sharpe ratio	2.13x
Sortino ratio	4.18
Total Return	-78.82%
Tr YTD	18.78
Tr1m	35.49%
Tr1w	57.33%
Tr3m	52.01%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	10
Analyst Count Top	5
Analyst Price Target Top	$49.6
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.01
Operating Income	$-72.9M
Operating margin	-123,601.7
Price target	$44.89
Price Target Change	$108
Price Target Change Top	$130

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	23,635,127%
Float Percent	88.47%
Shares Insiders	2.54%
Shares Institutions	88.69%
Shares Out	26,714,337
Shares Qo Q	30.22%
Shares Yo Y	78.82%
Short Float	22.16%
Short Ratio	5.93
Short Shares	19.61

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-65.1M
Average Volume	2,093,811.15x
Bv Per Share	4.49
Ch10y	-99.8
Ch1m	35.49
Ch1w	57.33
Ch1y	384.7
Ch3m	52.01
Ch3y	-96.54
Ch5y	-99.72
Ch6m	43.32
Change	-5.68%
Change From Open	-5.15
Close	22.87
Days Gap	-0.57
Depreciation Amortization	344,000
Dollar Volume	38,400,057.2
Earnings Date	2026-05-22
Earnings Time	bmo
EBIT	$-72.9M
EBITDA	$-72.6M
EPS	$-5.84
F Score	1
FCF	$-51.5M
FCF EV Yield	-10.76x
FCF Per Share	$-1.93
Financing CF	14,587,000
Fiscal Year End	December
Founded	2,011
Goodwill	10,502,000
Income Tax	$165,000
Investing CF	-81,720,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-23
Last Report Date	2025-12-31
Last Split Date	2023-12-29
Last Split Type	Reverse
Last10k Filing Date	2026-03-23
Ma150	16.15
Ma150ch	33.57%
Ma20	15.27
Ma20ch	41.24%
Net CF	-118,591,000
Next Earnings Date	2026-05-22
Open	22.74
Optionable	Yes
Position In Range	29.65
Post Close	21.57
Postmarket Change Percent	-0.97
Postmarket Price	$21.36
Ppne	460,000
Pre Close	22.87
Price Date	2026-05-08
Ptbv Ratio	7.94
Relative Volume	0.85x
Revenue	59,000x
SBC By Revenue	23,086.44x
Share Based Comp	13,621,000
Tax By Revenue	279.66x
Tr6m	43.32%
Us State	Pennsylvania
Volume	1,780,253
Z Score	-4.18

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AVTX pay a dividend?

Capital-return profile for this ticker.

Performance

AVTX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AVTX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+88.7%

Float: +88.5% of shares outstanding

Insider ownership

+2.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AVTX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

71.1

Above 70: short-term overbought

Price vs 200-day MA

+48.1%

50/200-day relationship not available

Beta (5Y)

0.79

Less volatile than the market

Sharpe ratio

2.13

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AVTX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AVTX stock rating?

Avalo Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AVTX analysis?

The full report lives at /stocks/AVTX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AVTX?

The latest report frames AVTX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AVTX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.